What the FDA labels say about taking them together
Levothyroxine and semaglutide
Semaglutide's FDA label (Ozempic) of January 30, 2026 names levothyroxine in its drug interactions section; the levothyroxine labels PlainMeds reads (4) do not name semaglutide. The semaglutide label: “Levothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered with semaglutide tablets in a drug interaction study.”
Check it at the source: the levothyroxine FDA label on DailyMed (effective February 20, 2024, AbbVie Inc.); the semaglutide FDA label on DailyMed (effective July 30, 2026, A-S Medication Solutions).
What does the levothyroxine label say about semaglutide?
Levothyroxine's label (effective February 20, 2024) and its 3 other brand-application labels do not name semaglutide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Synthroid), AbbVie Inc., effective February 20, 2024 (SPL set 1e11ad30-1041-4520-10b0-8f9d30d30fcc), via openFDA; the full label on DailyMed
What does the semaglutide label say about levothyroxine?
Ozempic label (Novo Nordisk Pharmaceutical Industries, LP, January 30, 2026), drug interactionsLevothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered with semaglutide tablets in a drug interaction study [see Clinical Pharmacology ( 12.3 )].
Source: FDA drug label (Ozempic, NDA213051), Novo Nordisk Pharmaceutical Industries, LP, effective January 30, 2026 (SPL set 27f15fac-7d98-4114-a2ec-92494a91da98), via openFDA
Source: FDA drug label (Ozempic), NDA209637 (Novo), as published by A-S Medication Solutions, effective July 30, 2026 (SPL set 42bdd912-2393-44c4-b7e0-47672ca28991), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Levothyroxine | Semaglutide | |
|---|---|---|
| Labeled for | Hypothyroidism | Type 2 diabetes, Heart attack and coronary artery disease, Chronic kidney disease, Weight management |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0588 per tablet 112 mcg tablet | $331.99 per mL 0.25-0.5 mg/dose (2 mg/3 mL) pen |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once